[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355624-105":59,"doc-detail-355624-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","different-immune-cells-modified-with-chimeric-antigen-receptors-are-being-applied-to-ovarian-cancer-which-is-the-most-effective-review","Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer - Which Is the Most Effective - review","","Ovarian cancer (OC), a highly lethal gynecological malignancy, presents major therapeutic challenges in advanced stages due to frequent recurrence and metastatic behavior. The review highlights rising interest in CAR-based cell immunotherapy and explains how genetically modified CAR molecules enable immune targeting of tumor antigens. It contrasts CAR-T, CAR-NK, and CAR-m therapies, focusing on mechanism, clinical strengths, and key technical limits. Safety concerns for CAR-T, including off-target effects, tumor immune barriers, cytokine release syndrome, and neurotoxicity, are discussed alongside potential advantages of NK and macrophage approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/different-immune-cells-modified-with-chimeric-antigen-receptors-are-being-applied-to-ovarian-cancer-which-is-the-most-effective-review/355624/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/different-immune-cells-modified-with-chimeric-antigen-receptors-are-being-applied-to-ovarian-cancer-which-is-the-most-effective-review/355624.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR-based immunotherapy gaining attention in ovarian cancer treatment?","Question",{"text":112,"@type":113},"Ovarian cancer has a high lethality profile with delayed diagnosis and limited options in advanced stages. Advances in chimeric antigen receptor (CAR)-based cell therapy have made immunotherapy increasingly relevant.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the clinical use of CAR-T therapy in ovarian cancer?",{"text":117,"@type":113},"Major constraints include off-target effects due to insufficient tumor-specific antigens and serious toxicities such as tumor immune barriers, cytokine release syndrome, and neurotoxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"How do CAR-NK and CAR-macrophage approaches address drawbacks seen in CAR-T?",{"text":121,"@type":113},"CAR-NK killing integrates CAR-dependent and non-dependent pathways, helping avoid severe CRS and neurotoxicity. CAR-m therapy may directly infiltrate and phagocytose tumors while also modulating the immunosuppressive microenvironment to shift M2-like TAMs toward an anti-tumor M1 phenotype.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355624,1790197984,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nDifferent Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?  \nLiying Wang1,2,3  | Yisen Cao4 | Yuan Ren1,2,3 | Yuhang Zhang5 | Liang Wang1,2,3  \n1Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China | 2Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital (Fujian Women and Children's Hospital), Fuzhou, Fujian, China | 3Fujian Clinical Research Center for Gynecological Oncology, Fujian Maternity and Child Health Hospital (Fujian Obstetrics and Gynecology Hospital), Fuzhou, Fujian, China | 4Fujian Medical University, Fuzhou, Fujian, China | 5The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China  \nCorrespondence: Liang Wang ([wangliang7012@mails.jlu.edu.cn](wangliang7012@mails.jlu.edu.cn))  \nReceived: 3 September 2025 | Revised: 14 April 2026 | Accepted: 21 April 2026  \nKeywords: CAR | CAR-macrophage | CAR-NK | CAR-T | ovarian cancer  \nABSTRACT  \nOvarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over-the-counter Chimeric Antigen Receptor (CAR)-based cell therapy. At the heart of CAR-T Cell (CAR-T) immunotherapy is genetically modified CAR molecules that enable immune cells to target and recognize tumor antigens. Based on such strategies, CAR-T therapies have developed rapidly in hematological oncology and are gradually being extended to solid tumors. Despite their potential in OC treatment, several factors, including off-target effects attributable to the lack of Tumor-Specific Antigens (TSAs), as well as severe side effects such as tumor immune barriers, Cytokine Release Syndrome (CRS), and neurotoxicity, have been established to limit the clinical use of CAR-T therapies. Moreover, compared to CAR-T, CAR-Natural Killer (NK) and CAR-Macrophage (M) therapies have distinct advantages. The killing mechanism of NK cells integrates both CAR-dependent and non-dependent pathways, avoiding severe CRS and neurotoxicity. Furthermore, besides directly phagocytosing tumors due to its strong ability to infiltrate tumors, CAR-M therapy could also effectively improve the Immunosuppressive Microenvironment (IME) via immunomodulatory factor secretion to remodel M2-type Tumor-Associated Macrophages (TAMs) into the M1 phenotype with anti-tumor function. In this review, we systematically describe the research progress in CAR-T therapy for OC and compare the similarities and differences of three types of cellular therapies (CAR-T, CAR-NK, and CAR-M) regarding their mechanisms of action, clinical advantages, and technological bottlenecks. We hope that our findings will provide a theoretical basis for optimizing immunotherapeutic strategies for OC.  \n[Trial Registration:](Trial Registration: ClinicalTrials.gov)[ ClinicalTrials.gov](Trial Registration: ClinicalTrials.gov) identifier: NCT03585764  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71897 1 of 17  \n[https://doi.org/10.1002/cam4.71897](https://doi.org/10.1002/cam4.71897)  \n1 | Introduction  \nOvarian Cancer (OC), the eight","cbCaic9t08cB0NAi","https://ap.wps.com/l/cbCaic9t08cB0NAi","pdf",1256621,17,"English","# Introduction\n## Tumor Immune Microenvironment and immune cell antitumor mechanisms\n# CAR-based cell therapy for ovarian cancer\n## CAR-T: rationale and limitations\n## CAR-NK: mechanisms and advantages\n## CAR-M: mechanisms and advantages\n# Comparative analysis and outlook","[{\"question\":\"Why is CAR-based immunotherapy gaining attention in ovarian cancer treatment?\",\"answer\":\"Ovarian cancer has a high lethality profile with delayed diagnosis and limited options in advanced stages. Advances in chimeric antigen receptor (CAR)-based cell therapy have made immunotherapy increasingly relevant.\"},{\"question\":\"What limits the clinical use of CAR-T therapy in ovarian cancer?\",\"answer\":\"Major constraints include off-target effects due to insufficient tumor-specific antigens and serious toxicities such as tumor immune barriers, cytokine release syndrome, and neurotoxicity.\"},{\"question\":\"How do CAR-NK and CAR-macrophage approaches address drawbacks seen in CAR-T?\",\"answer\":\"CAR-NK killing integrates CAR-dependent and non-dependent pathways, helping avoid severe CRS and neurotoxicity. CAR-m therapy may directly infiltrate and phagocytose tumors while also modulating the immunosuppressive microenvironment to shift M2-like TAMs toward an anti-tumor M1 phenotype.\"}]","Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer - Which Is the Most Effective - review | PDF",1790120188,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ad2f86c6a25b3d08970d560db055437.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a880452a206cd57fb9756e8a1174e3c9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/214adc19634e7d06ea02958337864a69.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8282e1d4863d639e53b38604cd74effb.webp",980,1287]